Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...

The scale of the problem has led analysts to predict that the market for RSV vaccines could eventually be worth several billion dollars a year. In trials, GSK’s vaccine significantly reduced the ...

Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported ...

In 2023, global sales of RSV vaccines reached USD 2.46 billion, and according to industry consultants, the market size is expected to grow to approximately USD 16.7 billion by 2030. The mRNA ...

caused by RSV through day 150 in healthy pre-term and full-term infants compared to placebo. The company plans to file the data with global regulatory authorities, setting up a possible market ...